IDORSIA AG SF-,05/ CH0363463438 /
| 2024-05-15 10:40:02 PM | Chg. +0.038 | Volume | Bid10:40:02 PM | Ask10:40:02 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 2.312EUR | +1.67% | - Turnover: - |
2.312Bid Size: - | 2.390Ask Size: - | -EUR | - | - |
GlobeNewswire
02-28
Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire
2023-11-03
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...
GlobeNewswire
2022-02-08
Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...
GlobeNewswire
2022-01-26
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and ...
GlobeNewswire
2022-01-10
Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – ...
GlobeNewswire
2022-01-10
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults ...
GlobeNewswire
2021-07-27
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a f...
GlobeNewswire
2021-07-20
Invitation to Idorsia's half year financial results 2021 webcast and conference call
GlobeNewswire
2021-06-28
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardi...
GlobeNewswire
2021-06-09
Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
GlobeNewswire
2021-04-22
Idorsia announces financial results for the first quarter 2021 – substantial progress made across th...
GlobeNewswire
2021-03-10
FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult...
GlobeNewswire
2021-01-11
Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the nea...
GlobeNewswire
2020-11-23
Idorsia announces positive results of the two Japanese registration studies with clazosentan
GlobeNewswire
2020-09-02
Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-...
GlobeNewswire
2020-08-31
Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United Stat...
GlobeNewswire
2020-07-06
Idorsia announces positive results in the second Phase 3 study of daridorexant
GlobeNewswire
2019-05-03
Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved
